Home › Bio-Path Holdings To Initiate Development Of Liposomal Bcl-2 In Follicular Lymphoma
 

Keywords :   


Bio-Path Holdings To Initiate Development Of Liposomal Bcl-2 In Follicular Lymphoma

2014-12-29 02:22:44| drugdiscoveryonline Home Page

Bio-Path Holdings, Inc., (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, recently announced that it has initiated development of Liposomal Bcl-2 as a treatment for follicular lymphoma

Tags: development holdings initiate lymphoma

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
12.05Shein suppliers still work 75-hour weeks - report
12.05Is social media worth paying for?
12.05'I'm stuck in my flat due to 4k service charge'
12.05Switzer Ranch staying resilient with long-term outlook
12.05BIF announces Seedstock, Commercial Producer award finalists
11.05Weekly Recap: Hempel, Sherwin-Williams Top This Weeks Stories
11.05LG CHI Color Master Factory Is Awarded Patent
11.05AgriWebb raises $7.2m to fuel further innovation in sustainable beef production
More »